摘要
【目的】观察聚乙二醇干扰素α-2a(pegylated interferonα-2a,PEG-IFNα-2a)联合利巴韦林(ribavirin,RBV)治疗糖尿病合并慢性丙型肝炎的病毒学应答、生化学影响及其安全性,以及标准疗程干扰素抗病毒治疗前后患者空腹血糖的变化。【方法】23例慢性丙型肝炎合并糖尿病患者为治疗组,给予PEG-IFN联合RBV治疗48周,同期就诊的17例非抗病毒治疗的慢性丙型肝炎合并糖尿病患者为对照组,给予复方甘草酸苷静脉及口服治疗,检测并分析两组4、12、48周时HCVRNA水平和持续病毒学应答率、肝功能各项指标及血糖情况。【结果】治疗组HCVRNA下降水平及病毒学应答优于对照组,疗程结束后随访24周,治疗组持续病毒学应答率为47.7%,生化学指标改善,且持续病毒学应答者血糖平稳,部分糖尿病病情好转。【结论】干扰素联合利巴韦林对慢性丙型肝炎伴糖尿病患者的治疗是安全有效的。故合并糖尿病慢性丙型肝炎患者可通过积极抗病毒治疗延缓肝病进展,同时良好的病毒学应答还可遏制糖尿病恶化,促进患者康复。
[Objective] To observe the virologic response rate of PEG-interferon ct-2a and ribavirin （RBV） in treatment of chronic hepatitis C with diabetes, and after the treatment what changes of blood glucose levels. [Methods]40 case of chronic hepatitis C and diabetes mellitus were divided into two groups,one group（23 patients） was given Peg- IFN combined with RBV for 48 weeks, analysis of HCV RNA on baseline and treatment 4,12,48 weeks , the other group（17patients） was given compound Glycyrrhizin, observe the changes of liver function and blood glucose. [ Results ] The HCVRNA of treatment group was decreased, and virologic response were better than the control group, blood glucose and other indicators had no significant difference between two groups, SVR of treatment group was 47.7%, the blood sugar steady for the patients of SVR. [Conclution] The treatment of interferon and ribavirin is safe and effective for diabetic patients with chronic hepatitis C. Chronic hepatitis C patients with diabetes through active antiviral therapy to delay the progression of liver disease, while a good virological response can be to curb diabetes deterioration, and promote the rehabilitation of the patients.
出处
《武警后勤学院学报（医学版）》
CAS
2013年第3期207-209,共3页
Journal of Logistics University of PAP（Medical Sciences）
